Testosterone intranasal (low-dose) - Acerus Pharmaceuticals
Alternative Names: MPP-14; Noseafix; TBS-2; TefinaLatest Information Update: 13 Nov 2021
At a glance
- Originator Mattern Pharmaceuticals
- Developer Acerus Pharmaceuticals; Trimel Biopharma
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Female sexual dysfunction
Highest Development Phases
- Phase II Anorgasmia
- No development reported Decreased libido
Most Recent Events
- 19 Sep 2019 Tefina™ is still in phase II trials for Anorgasmia in Australia, Canada and USA (Intranasal) (Acerus Pharmaceuticals pipeline, September 2019)
- 05 Apr 2018 Testosterone intranasal (low-dose) - Acerus Pharmaceuticals is available for licensing as of 05 Apr 2018. www.aceruspharma.com
- 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals